King's College London

Research portal

Inflammation associated with coronary heart disease predicts onset of depression in a three-year prospective follow-up: A preliminary study

Research output: Contribution to journalArticle

Standard

Inflammation associated with coronary heart disease predicts onset of depression in a three-year prospective follow-up : A preliminary study. / Sforzini, Luca; Pariante, Carmine M.; Palacios, Jorge E.; Tylee, Andre; Carvalho, Livia A.; Viganò, Caterina A.; Nikkheslat, Naghmeh.

In: Brain, Behavior, and Immunity, Vol. 81, 01.10.2019, p. 659-664.

Research output: Contribution to journalArticle

Harvard

Sforzini, L, Pariante, CM, Palacios, JE, Tylee, A, Carvalho, LA, Viganò, CA & Nikkheslat, N 2019, 'Inflammation associated with coronary heart disease predicts onset of depression in a three-year prospective follow-up: A preliminary study', Brain, Behavior, and Immunity, vol. 81, pp. 659-664. https://doi.org/10.1016/j.bbi.2019.07.023

APA

Sforzini, L., Pariante, C. M., Palacios, J. E., Tylee, A., Carvalho, L. A., Viganò, C. A., & Nikkheslat, N. (2019). Inflammation associated with coronary heart disease predicts onset of depression in a three-year prospective follow-up: A preliminary study. Brain, Behavior, and Immunity, 81, 659-664. https://doi.org/10.1016/j.bbi.2019.07.023

Vancouver

Sforzini L, Pariante CM, Palacios JE, Tylee A, Carvalho LA, Viganò CA et al. Inflammation associated with coronary heart disease predicts onset of depression in a three-year prospective follow-up: A preliminary study. Brain, Behavior, and Immunity. 2019 Oct 1;81:659-664. https://doi.org/10.1016/j.bbi.2019.07.023

Author

Sforzini, Luca ; Pariante, Carmine M. ; Palacios, Jorge E. ; Tylee, Andre ; Carvalho, Livia A. ; Viganò, Caterina A. ; Nikkheslat, Naghmeh. / Inflammation associated with coronary heart disease predicts onset of depression in a three-year prospective follow-up : A preliminary study. In: Brain, Behavior, and Immunity. 2019 ; Vol. 81. pp. 659-664.

Bibtex Download

@article{64e8ec9c094644a7b97bd6dfd69b0bc6,
title = "Inflammation associated with coronary heart disease predicts onset of depression in a three-year prospective follow-up: A preliminary study",
abstract = "Depression frequently co-occurs with coronary heart disease (CHD), worsening clinical outcomes of both, and inflammation has been proposed as a biological link between these two disorders. The aim of the present study was to investigate the role of inflammation in the development of depression in CHD patients during a 3-year follow-up. We examined the inflammatory biomarker, high-sensitivity C-reactive protein (hsCRP), measured at baseline, as a potential predictor of later onset of depression. We recruited 89 CHD patients, who were assessed at baseline and then every 6 months, for three years. The sample included, at baseline, 25 depressed and 64 non-depressed CHD patients, as confirmed by Clinical Interview Schedule Revised (CIS-R). Depressive symptoms were assessed at baseline and all follow-up points by the Patient Health Questionnaire-9 (PHQ-9). In all CHD patients (n = 89), we found a significant positive correlation between hsCRP levels and the severity of depressive symptoms at baseline (PHQ-9, r = 0.23, p = 0.032). During follow-up, n = 21 patients (of the 64 non-depressed at baseline) developed depression, defined as being PHQ-9 positive (a score ≥ 10) in at least one follow-up assessment. Of these, n = 9 subjects were defined as developing clinically-significant depression, that is, having a positive PHQ-9 in at least 3 of the 6 follow-up assessments, implying a duration of symptoms of at least one year. We found that increased hsCRP values at baseline predicted future onset of depression. Specifically, baseline hsCRP values were higher in patients who later developed clinically-significant depression (mean ± SD; 6.76 ± 6.52 mg/L) compared with never-depressed (2.77 ± 3.13 mg/L; F(1,48) = 7.29, p = 0.010), even after controlling for baseline PHQ-9 scores. In conclusion, inflammation in CHD patients is associated with future development of clinically-significant depression. HsCRP, a reliable and ready-to-use biological marker of inflammation, may help to identify depression high-risk phenotypes even among CHD patients, who already have high baseline inflammation. Our study conveys important preliminary findings that will require further replication but that have the potential to affect the mental and physical health of a vulnerable group of individuals.",
keywords = "C-reactive protein, Coronary heart disease, Depression, Inflammation, Inflammatory markers",
author = "Luca Sforzini and Pariante, {Carmine M.} and Palacios, {Jorge E.} and Andre Tylee and Carvalho, {Livia A.} and Vigan{\`o}, {Caterina A.} and Naghmeh Nikkheslat",
year = "2019",
month = "10",
day = "1",
doi = "10.1016/j.bbi.2019.07.023",
language = "English",
volume = "81",
pages = "659--664",
journal = "Brain Behavior and Immunity",
issn = "0889-1591",
publisher = "ACADEMIC PRESS INC",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Inflammation associated with coronary heart disease predicts onset of depression in a three-year prospective follow-up

T2 - A preliminary study

AU - Sforzini, Luca

AU - Pariante, Carmine M.

AU - Palacios, Jorge E.

AU - Tylee, Andre

AU - Carvalho, Livia A.

AU - Viganò, Caterina A.

AU - Nikkheslat, Naghmeh

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Depression frequently co-occurs with coronary heart disease (CHD), worsening clinical outcomes of both, and inflammation has been proposed as a biological link between these two disorders. The aim of the present study was to investigate the role of inflammation in the development of depression in CHD patients during a 3-year follow-up. We examined the inflammatory biomarker, high-sensitivity C-reactive protein (hsCRP), measured at baseline, as a potential predictor of later onset of depression. We recruited 89 CHD patients, who were assessed at baseline and then every 6 months, for three years. The sample included, at baseline, 25 depressed and 64 non-depressed CHD patients, as confirmed by Clinical Interview Schedule Revised (CIS-R). Depressive symptoms were assessed at baseline and all follow-up points by the Patient Health Questionnaire-9 (PHQ-9). In all CHD patients (n = 89), we found a significant positive correlation between hsCRP levels and the severity of depressive symptoms at baseline (PHQ-9, r = 0.23, p = 0.032). During follow-up, n = 21 patients (of the 64 non-depressed at baseline) developed depression, defined as being PHQ-9 positive (a score ≥ 10) in at least one follow-up assessment. Of these, n = 9 subjects were defined as developing clinically-significant depression, that is, having a positive PHQ-9 in at least 3 of the 6 follow-up assessments, implying a duration of symptoms of at least one year. We found that increased hsCRP values at baseline predicted future onset of depression. Specifically, baseline hsCRP values were higher in patients who later developed clinically-significant depression (mean ± SD; 6.76 ± 6.52 mg/L) compared with never-depressed (2.77 ± 3.13 mg/L; F(1,48) = 7.29, p = 0.010), even after controlling for baseline PHQ-9 scores. In conclusion, inflammation in CHD patients is associated with future development of clinically-significant depression. HsCRP, a reliable and ready-to-use biological marker of inflammation, may help to identify depression high-risk phenotypes even among CHD patients, who already have high baseline inflammation. Our study conveys important preliminary findings that will require further replication but that have the potential to affect the mental and physical health of a vulnerable group of individuals.

AB - Depression frequently co-occurs with coronary heart disease (CHD), worsening clinical outcomes of both, and inflammation has been proposed as a biological link between these two disorders. The aim of the present study was to investigate the role of inflammation in the development of depression in CHD patients during a 3-year follow-up. We examined the inflammatory biomarker, high-sensitivity C-reactive protein (hsCRP), measured at baseline, as a potential predictor of later onset of depression. We recruited 89 CHD patients, who were assessed at baseline and then every 6 months, for three years. The sample included, at baseline, 25 depressed and 64 non-depressed CHD patients, as confirmed by Clinical Interview Schedule Revised (CIS-R). Depressive symptoms were assessed at baseline and all follow-up points by the Patient Health Questionnaire-9 (PHQ-9). In all CHD patients (n = 89), we found a significant positive correlation between hsCRP levels and the severity of depressive symptoms at baseline (PHQ-9, r = 0.23, p = 0.032). During follow-up, n = 21 patients (of the 64 non-depressed at baseline) developed depression, defined as being PHQ-9 positive (a score ≥ 10) in at least one follow-up assessment. Of these, n = 9 subjects were defined as developing clinically-significant depression, that is, having a positive PHQ-9 in at least 3 of the 6 follow-up assessments, implying a duration of symptoms of at least one year. We found that increased hsCRP values at baseline predicted future onset of depression. Specifically, baseline hsCRP values were higher in patients who later developed clinically-significant depression (mean ± SD; 6.76 ± 6.52 mg/L) compared with never-depressed (2.77 ± 3.13 mg/L; F(1,48) = 7.29, p = 0.010), even after controlling for baseline PHQ-9 scores. In conclusion, inflammation in CHD patients is associated with future development of clinically-significant depression. HsCRP, a reliable and ready-to-use biological marker of inflammation, may help to identify depression high-risk phenotypes even among CHD patients, who already have high baseline inflammation. Our study conveys important preliminary findings that will require further replication but that have the potential to affect the mental and physical health of a vulnerable group of individuals.

KW - C-reactive protein

KW - Coronary heart disease

KW - Depression

KW - Inflammation

KW - Inflammatory markers

UR - http://www.scopus.com/inward/record.url?scp=85069822384&partnerID=8YFLogxK

U2 - 10.1016/j.bbi.2019.07.023

DO - 10.1016/j.bbi.2019.07.023

M3 - Article

AN - SCOPUS:85069822384

VL - 81

SP - 659

EP - 664

JO - Brain Behavior and Immunity

JF - Brain Behavior and Immunity

SN - 0889-1591

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454